Immune Design Announces Positive Data from Three Phase 1

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Immune Design Announces Positive Data from Three Phase 1 Studies at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting

SEATTLE and SOUTH SAN FRANCISCO, Calif., May 13, 2015 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq: IMDZ ) today announced that positive clinical data from three immuno-oncology Phase 1 studies will be presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, which will take place May 29 to June 2, 2015 in Chicago.

The three trials provide first-in-human clinical data with the company's immuno-oncology cancer agents, LV305, G305, and G100, which are designed to generate anti-tumor immunity. LV305 and G305 are individually active agents that combine to form the product candidate called CMB305, the company's prime-boost approach targeting the tumor-associated antigen, NY-ESO-1. G100, in contrast, is a potent toll-like receptor-4 (TLR4) agonist that is being administered intratumorally to activate local and systemic immunity. Data from these initial Phase 1 trials to be presented at ASCO include:

-- LV305:

  • Favorable safety profile with only Grade 1 or 2 adverse events observed in the twelve patients treated in this dose-escalation trial evaluating three different dose levels of LV305.
  • CD4 or CD8 specific T-cell responses were observed after therapy in eight of eleven (73%) evaluable patients.  Four of the six patients treated with the mid or high dose levels of LV305 developed de novo CD8 T-cell responses against NY-ESO-1. As expected, the therapy had no effect on anti-NY-ESO-1 antibody levels.
  • Of the twelve patients with various types of soft tissue sarcoma expressing NY-ESO-1 who were enrolled and treated:
    • Four of six patients with evidence of tumor growth prior to LV305 treatment stabilized and stopped progression with the longest at 347+ days; tumor regression up to 13.8% was observed in one patient.
    • Eight of twelve (67%) patients achieved a best response of stable disease (SD) with a median duration of 208 days (range: 139-347+) and the progression-free rate (PFR) of all twelve patients at six months was at least 42% 1 .
    • Although a small study and differences in the patient population exist, the observed PFR of at least 42% compares favorably to the historical PFR in the analysis of a large group of patients reported by Van Glabbeke, et al. 2 , where active agents for first- and second-line treatment exhibited a PFR of > 30-56% (histology dependent) and > 14% at six months, respectively (importantly, the LV305 study consisted of patients who had all received at least one prior treatment).

-- G305:

  • Favorable safety profile with only Grade 1 or 2 adverse events observed in the twelve patients treated in this dose escalation trial evaluating three different dose levels of G305 in patients with sarcoma, melanoma, urothelial or ovarian cancer.
  • Nine of twelve (75%) patients had a significant humoral response to NY-ESO-1 post therapy, and five of eleven (45%) evaluable patients also had a significant CD4 T-cell response against NY-ESO-1.
  • Eight of twelve (67%) patients achieved a best response of SD; median duration of SD was 245+ days (range 161 to 365+), including in one patient with ovarian cancer with a significant and sustained reduction of the CA125 biomarker.

-- G100:

  • Favorable safety profile with only Grade 1 or 2 adverse events was observed in the eight patients (including two with loco-regional and six with metastatic disease) treated with single dose level of intratumoral G100 in this pilot trial of patients with Merkel cell carcinoma (MCC).
  • Intratumoral G100 as a single agent resulted in a pathologic CR in 1 patient with loco-regional disease and a 28% reduction of tumor in a patient with metastases. 
  • The combined therapy of G100 followed by radiation and/or surgery in the eight MCC patients resulted in an objective response rate (ORR) of 50%.

The data from all three Phase 1 studies will be presented at ASCO in the Developmental Therapeutics – Immunotherapy session, which is part of the Developmental Therapeutics and Translational Research track, taking place Saturday, May 30, 2015. The data presented in the poster sessions will substantially exceed the data in the published abstracts.

CMB305

Having established the safety and individual immunologic activity of LV305 and G305, Immune Design initiated a new Phase 1B study of the product candidate CMB305 earlier this year. Based on preclinical models, the sequential combination of LV305 and G305 is expected to be synergistic and more potent as a prime-boost approach than the individual agents alone.

G100

Immune Design plans to complete the enrollment of the ongoing Phase 1 clinical trial of G100 in patients with Merkel cell carcinoma. Based on the encouraging response rate observed thus far, Immune Design also intends to expand this novel approach in a Phase 1/2 trial of G100 in non-Hodgkin's lymphoma.

Immuno-Oncology at Immune Design

All of Immune Design's product candidates are designed to work in vivo and activate the immune system via the induction and/or expansion of anti-tumor CD8 T cells, and are intended to be "off-the-shelf" therapies in contrast to certain other T cell approaches that require individualized, complicated ex vivo manipulation.

ASCO Presentation Information

Phase I, first-in-human trial of LV305 in patients with advanced or metastatic cancer expressing NY-ESO-1

Abstract #: 3021  Session Type: Poster Discussion Session  Date and Time: Saturday, May 30, 2015 3 p.m. – 4:15 p.m.  Location: S406

Session Type: Poster Session  Date and time: Saturday, May 30, 8 a.m. – 11:30 a.m.  Location: S Hall A  Poster Board: #347

Presenter: Neeta Somaiah, M.D. Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center

A first-in-human phase 1 dose-escalating trial of G305 in patients with solid tumors expressing NY‑ESO‑1

Abstract #: 3073  Session Type: Poster Session  Date and time: Saturday, May 30, 8 a.m. – 11:30 a.m.  Location: S Hall A  Poster Board: #399  Presenter: Amit Mahipal, M.D. Moffitt Cancer Center

Pilot study of intratumoral G100, toll-like receptor-4 (TLR4) agonist, therapy in patients with Merkel cell carcinoma (MCC)

Abstract #: 3083  Session Type: Poster Session  Date and time: Saturday, May 30, 8 a.m. – 11:30 a.m.  Location: S Hall A  Poster Board: #409  Presenter: Shailender Bhatia, MD, University of Washington/Fred Hutchinson Cancer Research Center

Immune Design Post-ASCO Clinical Research Update

Immune Design will host a post-ASCO Clinical Research Update on Wednesday, June 2, 2015 at 5:30 p.m. in New York to review the three Phase 1 data sets presented at ASCO. Participants will include Immune Design senior leadership and principal investigators from ASCO-selected submissions, Dr. Amit Mahipal and Dr. Neeta Somaiah. The event will be webcast and available online from the investor relations section of the company website at http://ir.immunedesign.com/events.cfm .

About Immune Design

Immune Design is a clinical-stage immunotherapy company employing next-generation in vivo approaches to enable the body's immune system to fight disease. The company's technologies are engineered to activate the immune system's natural ability to generate and/or expand antigen-specific cytotoxic T cells, while also enhancing other immune effectors, to fight cancer and other chronic diseases. CMB305 and G100, the two-pronged focus of Immune Design's ongoing immuno-oncology clinical programs, are the product of its two synergistic discovery platforms, ZVex TM and GLAAS TM . Immune Design has offices in Seattle and South San Francisco. For more information, visit www.immunedesign.com .

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Immune Design's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements regarding the prospects for product candidate CMB305 and potential implications of the data contained in Abstract No: 3083 to be presented at the American Society of Clinical Oncology (ASCO) 2015 Annual Meeting for future clinical studies; the timing and results of the Phase 1B trial of CMB305; patient enrollment of the Phase 1 trial of G100 and the timing of commencement of an additional Phase 1/2 trial of G100; and clinical development of Immune Design's product candidates. Many factors may cause differences between current expectations and actual results including unexpected safety or efficacy data observed during preclinical or clinical studies, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing competition, changes in the regulatory environment, failure of Immune Design's collaborators to support or advance collaborations or product candidates and unexpected litigation or other disputes. Other factors that may cause Immune Design's actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in more detail in Immune Design's filings with the U.S. Securities and Exchange Commission, including under the heading "Risk Factors" contained in the Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 31, 2015, and in subsequent filings. Except as required by law, Immune Design assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

Footnote and Citation :

1 Note that the total tumor burden in the LV305 study was restricted to <10cm and ECOG status was <2

2 Van Glabbeke,et al., European Journal of Cancer,, "Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas", 2002.

Media Contact Julie Rathbun Rathbun Communications 206-769-9219 Investor Contact Shari Annes Annes Associates 650-888-0902

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sivers Semiconductors: Strategy Behind 2027 AGM Plans

Updated Category News Views 174

Setting the Stage for a Crucial Year Ah, the dance of corporate governance—an arena where maneuvering is an art. Sivers Semiconductors AB, a name that's becoming synonymous with innovation in the photonics and wireless solutions sector, is prepping for its 2027 Annual General Meeting. Ahead of this pivotal event, they're forming a Nomination Committee to shape future...

Continue Reading
ZTE Reinvents Energy for AI Data Centers

Updated Category News Views 127

The Great Race: Power and AI in Sync Here we are, neck-deep in the AI era, where the demand for raw computing power just won’t quit. With every data-hungry application and supercharged algorithm, companies are scrambling to keep up. But there’s a nasty little dragon in this fairy tale—energy efficiency. ZTE isn’t just acknowledging this beast; they’re ready to...

Continue Reading
Caregiving's Financial Impact on Women: Insights from Cinergy

Updated Category News Views 65

Women Caregivers Face Financial Crossroads When it comes down to it, caregiving is one heck of a responsibility, particularly for women. It's about the sacrifices they make, not just in time but in financial security, too. Step away from a job to care for someone, and it's a dicey game you're playing with future income. The Cost of Generosity: Financial Impacts Cindy...

Continue Reading
Elite Robots Expands Global Reach with Mobile Manipulators

Updated Category News Views 112

Robots Hitting the Road? Picture this: robots that aren't just bolted to a factory floor but roam the production lines like tireless workers on wheels. That's what Elite Robots is betting on with their shiny new ELITEMISSION mobile manipulators. Not Just Any Old Robot These bad boys combine a robotic arm with an autonomous mobile platform. Think of an octopus getting off...

Continue Reading
Ballard's Q3 2026: Navigating Losses and Bold Moves

Updated Category News Views 69

Ballard’s Financial Puzzles in Q3 2026 Riding the rough waters of the third quarter in 2026, Ballard Power Systems set out its stall with some eyebrow-raising numbers. This ain't the bustling diner vibe we normally see for a thriving business. The results paint a cautious picture sprinkled with strategic shifts that demand a keen eye. GeoPura Acquisition: A Strategic...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 252

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading
Fluence Energy Faces Heat: Class Action Lawsuit Unfolds

Updated Category News Views 25

Fluence Energy's Difficult Waters Investors in Fluence Energy (NASDAQ: FLNC) are having a moment of reckoning, no doubt. November 2nd saw a nearly 9% drop in FLNC stock, further fueled by the sudden departures of the CEO and CFO just days earlier. This marks a bitter chapter for Fluence as its stock continues to bleed, leaving many wondering what seismic shifts are yet to...

Continue Reading
Nord Anglia Schools Shine with 13 Tes Awards Nominations

Updated Category News Views 7

Nord Anglia's Moment of Glory at Tes Awards You think you know the big players in the educational game? Well, guess again. Nord Anglia's come out swinging with a whopping 13 finalist nominations at the 2026 Tes Awards for International Schools. It ain't easy making waves in the education sector, but these folks are showing they've got what it takes to turn heads, not just...

Continue Reading
Ranger and Smith Unveil Tea-Infused Chocolate Bar

Updated Category News Views 11

Fresh Collaborations in Portland's Culinary Scene Ah, the sweet crossover in Portland's food scene is once again in the spotlight with a new entry that's sure to titillate taste buds. Ranger Chocolate Co. and Steven Smith Teamaker are at it again, rolling out a delectable creation that merges the poetic elegance of tea with the indulgent richness of chocolate. Welcome,...

Continue Reading
Palatin's Game-Changer: MC4R Agonist Hits the Stage

Updated Category News Views 62

Breaking New Ground in Obesity Treatment Palatin Technologies is stepping into the spotlight with some heavy ammunition in the fight against obesity. The company has just unveiled impressive preclinical data about their next-generation melanocortin-4 receptor (MC4R) agonists at the ObesityWeek® 2026 conference. This isn’t just your run-of-the-mill corporate...

Continue Reading

Top 5 Most Recently Viewed Articles

NVIDIA Set to Gain from Hyperscalers' Surge in AI Investments

Updated Category News Views 191

Massive Capital Expenditures Expected from Hyperscalers Recently, major hyperscalers have reported impressive third-quarter financial results, leading to significant updates regarding their capital expenditure (CapEx) plans as the AI market expands. Analysts are observing a dramatic increase in spending plans, with projections indicating that these companies might...

Continue Reading
JARS Cannabis Enhances Live Music Experience This Summer

Updated Category News Views 140

JARS Cannabis Expands Live Music Partnership The Michigan-based cannabis retailer, JARS Cannabis, is amplifying its engagement this summer by enhancing its partnership with 313 Presents. This strategic move aims to introduce a more vibrant presence at two of the region's iconic music venues: Pine Knob Music Theatre and the Michigan Lottery Amphitheatre at Freedom Hill....

Continue Reading
Significant Insights on Gender Differences in HoFH Research

Updated Category News Views 185

Groundbreaking Research Unveiled in Preventive Cardiology Journal The American Journal of Preventive Cardiology (AJPC) has published a groundbreaking study that delves into the crucial sex-based differences in homozygous familial hypercholesterolemia (HoFH). This pivotal research marks the first issue under the new leadership of Dr. Khurram Nasir as Editor-in-Chief and...

Continue Reading
Sugar Grove Ace Commemorates a Decade of Community Support

Updated Category News Views 90

Celebrate a Milestone: Sugar Grove Ace's 10th Anniversary Sugar Grove Ace is thrilled to celebrate its 10th anniversary with a community event that promises fun, excitement, and gratitude. This special gathering is set to take place on a Saturday in the near future, showcasing the store's dedication to its customers and the local community. Event Highlights The day will...

Continue Reading
Insightful Earnings Preview for Microvast Holdings (MVST)

Updated Category News Views 240

Understanding Microvast Holdings's Earnings Outlook Microvast Holdings (NASDAQ: MVST) is on the brink of releasing its next quarterly earnings report. Investors are eager to see how the company fares as speculation around performance intensifies. Let's delve into what to expect and the key indicators influencing stockholder sentiment. Earnings Expectations for the...

Continue Reading